Coherus Oncology to Present at Upcoming Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy CHRS?
Source: Newsfilter
- Conference Schedule: Coherus Oncology will present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, at 11:50 a.m. EDT, followed by the Citizens Life Sciences Conference in Miami on March 10, 2026, at 2:50 p.m. EDT, showcasing its latest advancements in oncology.
- Webcast Availability: All presentations will be accessible via webcast through the Investor Events Calendar section of the Coherus Oncology website, with replays available for approximately 90 days, ensuring investors can access key information and enhancing transparency.
- Product Strategy: Coherus Oncology's strategic focus is on driving sales of its PD-1 inhibitor LOQTORZI® in R/M Nasopharyngeal Carcinoma while advancing the development of new indications in combination with its pipeline candidates and partners, aiming to enhance sales multiples and synergies.
- Innovative Pipeline: The company is developing multiple antibody immunotherapy candidates, including Tagmokitug and Casdozokitug, currently in clinical trials for advanced solid tumors, demonstrating potential to enhance tumor immune responses and further solidify its market position in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.650
Low
4.00
Averages
5.50
High
7.00
Current: 1.650
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
Coherus Oncology to Present at Upcoming Conferences
- Conference Schedule: Coherus Oncology will present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, at 11:50 a.m. EDT, followed by the Citizens Life Sciences Conference in Miami on March 10, 2026, at 2:50 p.m. EDT, showcasing its latest advancements in oncology.
- Webcast Availability: All presentations will be accessible via webcast through the Investor Events Calendar section of the Coherus Oncology website, with replays available for approximately 90 days, ensuring investors can access key information and enhancing transparency.
- Product Strategy: Coherus Oncology's strategic focus is on driving sales of its PD-1 inhibitor LOQTORZI® in R/M Nasopharyngeal Carcinoma while advancing the development of new indications in combination with its pipeline candidates and partners, aiming to enhance sales multiples and synergies.
- Innovative Pipeline: The company is developing multiple antibody immunotherapy candidates, including Tagmokitug and Casdozokitug, currently in clinical trials for advanced solid tumors, demonstrating potential to enhance tumor immune responses and further solidify its market position in oncology.
See More
Coherus Oncology Prices $50.1 Million Public Offering
- Funding Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 each, raising a total of $50.1 million, with the transaction expected to close on February 17, 2026, aimed at supporting the commercialization of LOQTORIZ and ongoing clinical development.
- Revenue Growth: The company reported Q3 2025 net revenue of $11.6 million, a significant increase from $6.05 million in the previous quarter, reflecting strong market demand for LOQTORIZ and a recovery in overall business performance.
- Clinical Trial Results: LOQTORIZ demonstrated a median overall survival of 64.8 months in the JUPITER-02 trial, nearly double that of chemotherapy alone, reinforcing its position as the standard-of-care first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Future Milestones: Coherus plans to release initial data from the CHS-114 and LOQTORIZ combination therapy in HNSCC in H1 2026, which is expected to drive further development of its immuno-oncology programs and enhance its competitive edge in the market.
See More
Applied Materials Reports Strong Q1 Results, Shares Surge
- Strong Financial Results: Applied Materials reported first-quarter revenue of $7.01 billion, exceeding analyst expectations of $6.87 billion, indicating robust demand in the semiconductor equipment market and reinforcing its market leadership.
- Earnings Beat: The company posted adjusted earnings of $2.38 per share for the first quarter, surpassing the $2.20 estimate, reflecting improved cost control and operational efficiency, which is likely to attract more investor interest.
- Stock Surge: Following the earnings report, Applied Materials shares jumped 11.9% to $367.50 in pre-market trading, indicating a positive market sentiment towards the company's growth prospects, potentially boosting investor confidence further.
- Positive Q2 Guidance: The company issued second-quarter guidance above market expectations, demonstrating management's confidence in future performance, which is expected to drive more capital inflows and enhance its competitive position in the industry.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 per share, expecting to raise approximately $50.1 million in gross proceeds before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company is also granting underwriters a 30-day option to purchase an additional 4.29 million shares at the same price, a strategy that may enhance market demand and liquidity for its stock.
- Use of Proceeds: The net proceeds will support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its pipeline, and fund working capital and other general corporate purposes, demonstrating the company's strategic planning for future growth.
- Expected Closing Date: The offering is expected to close around February 17, 2026, subject to standard closing conditions, reflecting the company's cautious and forward-looking approach to capital operations.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has announced a public offering of 28,600,000 shares at a price of $1.75 per share, with expected gross proceeds of approximately $50.1 million, which will support ongoing commercialization and clinical development efforts.
- Underwriter Selection: The offering is being managed by TD Cowen, Guggenheim Securities, and Oppenheimer & Co., reflecting market confidence in Coherus' stock and potentially enhancing investor expectations for the company's future growth.
- Use of Proceeds: The proceeds from the offering will be utilized to support the commercialization of LOQTORZI®, continue clinical development, and for general corporate purposes, indicating strategic decisions aimed at expanding the company's product line and market share.
- Additional Share Option: The underwriters have a 30-day option to purchase an additional 4,290,000 shares at the same offering price, which further enhances the flexibility and potential revenue of the offering.
See More
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
Coherus Oncology to Present at Upcoming Conferences
- Conference Schedule: Coherus Oncology will present at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, at 11:50 a.m. EDT, followed by the Citizens Life Sciences Conference in Miami on March 10, 2026, at 2:50 p.m. EDT, showcasing its latest advancements in oncology.
- Webcast Availability: All presentations will be accessible via webcast through the Investor Events Calendar section of the Coherus Oncology website, with replays available for approximately 90 days, ensuring investors can access key information and enhancing transparency.
- Product Strategy: Coherus Oncology's strategic focus is on driving sales of its PD-1 inhibitor LOQTORZI® in R/M Nasopharyngeal Carcinoma while advancing the development of new indications in combination with its pipeline candidates and partners, aiming to enhance sales multiples and synergies.
- Innovative Pipeline: The company is developing multiple antibody immunotherapy candidates, including Tagmokitug and Casdozokitug, currently in clinical trials for advanced solid tumors, demonstrating potential to enhance tumor immune responses and further solidify its market position in oncology.
See More
Coherus Oncology Prices $50.1 Million Public Offering
- Funding Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 each, raising a total of $50.1 million, with the transaction expected to close on February 17, 2026, aimed at supporting the commercialization of LOQTORIZ and ongoing clinical development.
- Revenue Growth: The company reported Q3 2025 net revenue of $11.6 million, a significant increase from $6.05 million in the previous quarter, reflecting strong market demand for LOQTORIZ and a recovery in overall business performance.
- Clinical Trial Results: LOQTORIZ demonstrated a median overall survival of 64.8 months in the JUPITER-02 trial, nearly double that of chemotherapy alone, reinforcing its position as the standard-of-care first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Future Milestones: Coherus plans to release initial data from the CHS-114 and LOQTORIZ combination therapy in HNSCC in H1 2026, which is expected to drive further development of its immuno-oncology programs and enhance its competitive edge in the market.
See More
Applied Materials Reports Strong Q1 Results, Shares Surge
- Strong Financial Results: Applied Materials reported first-quarter revenue of $7.01 billion, exceeding analyst expectations of $6.87 billion, indicating robust demand in the semiconductor equipment market and reinforcing its market leadership.
- Earnings Beat: The company posted adjusted earnings of $2.38 per share for the first quarter, surpassing the $2.20 estimate, reflecting improved cost control and operational efficiency, which is likely to attract more investor interest.
- Stock Surge: Following the earnings report, Applied Materials shares jumped 11.9% to $367.50 in pre-market trading, indicating a positive market sentiment towards the company's growth prospects, potentially boosting investor confidence further.
- Positive Q2 Guidance: The company issued second-quarter guidance above market expectations, demonstrating management's confidence in future performance, which is expected to drive more capital inflows and enhance its competitive position in the industry.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 per share, expecting to raise approximately $50.1 million in gross proceeds before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company is also granting underwriters a 30-day option to purchase an additional 4.29 million shares at the same price, a strategy that may enhance market demand and liquidity for its stock.
- Use of Proceeds: The net proceeds will support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its pipeline, and fund working capital and other general corporate purposes, demonstrating the company's strategic planning for future growth.
- Expected Closing Date: The offering is expected to close around February 17, 2026, subject to standard closing conditions, reflecting the company's cautious and forward-looking approach to capital operations.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has announced a public offering of 28,600,000 shares at a price of $1.75 per share, with expected gross proceeds of approximately $50.1 million, which will support ongoing commercialization and clinical development efforts.
- Underwriter Selection: The offering is being managed by TD Cowen, Guggenheim Securities, and Oppenheimer & Co., reflecting market confidence in Coherus' stock and potentially enhancing investor expectations for the company's future growth.
- Use of Proceeds: The proceeds from the offering will be utilized to support the commercialization of LOQTORZI®, continue clinical development, and for general corporate purposes, indicating strategic decisions aimed at expanding the company's product line and market share.
- Additional Share Option: The underwriters have a 30-day option to purchase an additional 4,290,000 shares at the same offering price, which further enhances the flexibility and potential revenue of the offering.
See More
